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In the traditional Chinese medicine, the preparation Danggui
Longhui Wan, consisting of 11 herbal medicines, has been used
for the treatment of various chronic diseases (Chinese
Pharmacopoeia, edition 1995, Vol. 1). Danggui Longhui Wan was
shown to be clinically active in chronic myelocytic leukaemia
(CML) (Institute of Haematology, Chinese Academy of Medicinal
Sciences, 1979). The antileukaemic activity of the complex
mixture was found to be associated with one ingredient, Qing Dai
(Indigo naturalis), containing the well known blue dye indigo as
the main constituent (Chen and Xie, 1984). Further investigations
revealed that the antileukaemic principle was not the 2,2¢-bisindole
indigo, but could be traced to the minor constituent indirubin, a red
colored 3,2¢-bisindole isomer (Wu et al, 1979; Zheng et al, 1979).
In clinical trials with patients suffering from chronic myelocytic
and chronic granulocytic leukaemia, indirubin was reported to
induce complete remission in 26% and partial remission in 33% of
the 314 cases, showing only low toxicity and limited side effects
(Cooperative Group of Clinical Therapy of Indirubin, 1980).
Indirubin has been reported to inhibit DNA and protein synthesis
in various cell lines (Wu et al, 1980). However, the underlying
mechanism of action of indirubin has remained largely unknown. 
We have recently discovered that indirubin and its derivatives are
selective and potent inhibitors of cyclin-dependent kinases (Hoessel
et al, 1999). CDK1/cyclin B kinase isolated from starfish oocytes is
inhibited by indirubin with an IC50 value of 10 µM. Indirubin-3¢-
monoxime exhibited a higher inhibitory potency with an IC50 value
of 0.18 µM. The water-soluble derivative indirubin-5-sulfonate was
much more potent, exhibiting an IC50 value as low as 0.055 µM
(Hoessel et al, 1999). In the present study we investigated whether
in human tumour cells cyclin-dependent kinases are affected by
indirubin derivatives, to address the question whether this inhibition
is relevant for the growth inhibitory properties of these compounds. 
MATERIALS AND METHODS 
Chemicals 
Indirubin, indirubin-5-sulfonate and indirubin-3¢-monoxime were
synthesized as described previously (Hoessel et al, 1999). Olomou-
cine (2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine) and
nocodazole (methyl-[5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-
carbamate) were purchased from Sigma (Deisenhofen, Germany).
All compounds were dissolved in dimethyl sulfoxide (DMSO) 
Cell culture 
The human mammary carcinoma cell line MCF-7 and the large
cell lung tumour xenograft cell line LXFL529L (Fiebig et al,
1992) were cultured in RPMI 1640 medium with 10% fetal calf
serum (FCS) and 1% penicillin/streptomycin in humidified
incubators (37˚C, 5% CO2). Cell culture medium and supplements
were obtained from Gibco Life Technologies (Karlsruhe,
Germany). Cells were routinely tested for the absence of
mycoplasm contamination. For synchronization, cells at a density
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FCS. As an alternative synchronization method, cells were treated
with 0.5 µg ml–1 nocodazole for 16 h. Cells were released from the
block by removal of the respective medium, careful washing with
phosphate buffered saline (PBS), and by adding serum repleted
medium containing drug or vehicle. 
Sulforhodamine B assay 
Effects on cell growth were determined as described previously
(Skehan et al, 1990). Briefly, cells were seeded into 24-well plates
and allowed to grow for 24 h before treatment. Thereafter, cells
were incubated with the respective drug for 3 days in serum-
containing medium. Incubation was stopped by addition of
trichloro acetic acid. After 1 h at 4˚C, plates were washed 4 times
with water. The dried plates were stained with sulforhodamine B.
The dye was eluted and quantified photometrically at 570 nm.
Cytotoxicity was determined as percent survival, determined by
the number of treated over control cells ´ 100 (% T/C). 
Immunoprecipitation 
For immunoprecipitation, synchronized cells (1 ´ 107) were
washed with PBS and lysed at 4˚C in 0.5 ml lysis buffer (10 mM
Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 0.2 mM
PMSF, 0.2 mM sodium vanadate, 1% Triton ®X-100, 0.5%
Nonidet P-40). After centrifugation (10 min, 4˚C, 10 000 g), the
lysate, adjusted to 400 µg protein, was incubated for 1 h at 4˚C
with a mouse monoclonal antibody raised against human CDK1
(anti-CDK1; Dianova, Hamburg, Germany). The immune
complex was absorbed to protein G-coupled sepharose beads
(Sigma, Deisenhofen, Germany) for 1 h at 4˚C. Thereafter, the
beads were washed 3 times with PBS. 
Western blotting 
Immunoprecipitated proteins were eluted from the sepharose
beads by addition of 1% SDS and loaded onto a 12% SDS-
polyacrylamide gel. 
For determination of the total amount of CDK1 or cyclin B,
MCF-7 cells were grown onto 10 cm Petri dishes for 24 h and
subsequently synchronized by treatment with nocodazole for 16 h
(0.5 µg ml–1). Thereafter, the plates were washed with PBS and
incubated with indirubin-3¢-monoxime (5 µM) or the solvent
DMSO (final concentration 1%) for control. For every time point
(1 h, 3 h, 6 h and 24 h) one plate treated with indirubin-3¢-monoxime
and one of the DMSO treated plates were harvested and processed
in parallel. The plates were washed with PBS and than harvested
in 500 µl RIPA buffer (consisting of 150 mM NaCl, 1% Nonidet P-
40, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM Tris-HCl,
pH 7.5, 25 mM benzamidine, 0.5 µg ml–1 leupeptin, 0.7 µg ml–1
pepstatin, 2µg ml–1 aprotinin, 5 mg ml–1 trypsin soybean inhibitor,
2 mM phenylmethylsulfonyl fluoride, 50 mM NaF), homogenized
and centrifuged for 10 min (4˚C, 10 000 g). The supernatants (cell
lysate) were adjusted with respect to protein content, mixed with
the respective amount of 6-fold loading buffer and directly
subjected to electrophoresis on a 12% SDS-polyacrylamide gel. 
After electrophoresis the proteins were transferred onto a nitro-
cellulose membrane. After blocking with 4% bovine serum
albumin, membranes were incubated with the respective mono-
clonal antibody. For determination of the total cellular content of
CDK1, a mouse monoclonal antibody against human CDK1 (anti-
CDK1; Dianova, Hamburg, Germany) was used. The total cellular
level of cyclin B and the amount of cyclin B in complex with CDK1
were determined using a mouse monoclonal antibody against
human cyclin B (anti-cyclin B; Dianova, Hamburg, Germany). The
membranes were treated with the antibody solution for 1.5 h at room
temperature. The membranes were washed 3 times in TBST buffer
and incubated with anti-mouse IgG (H+L) peroxidase conjugate
(Roche Diagnostics, Mannheim, Germany) for 1 h at room tempera-
ture. The protein bands were detected by enhanced chemolumines-
cence (ECL, Amersham Buchler GmbH, Braunschweig, Germany),
using a Lumi-Imager™ with the LumiAnalyst 3.0 software for
quantification (Roche Diagnostics, Mannheim, Germany). Each
experiment was performed three times (different cell passages) and
the values are given as mean ± SE. 
Histone H1 kinase assay 
Histone H1 phosphorylation, as a measure for CDK1 activity,
was assayed using a kit from Biozol (Eching, Germany).
Immunoprecipitated CDK1 was resuspended in 10 µl assay dilu-
tion buffer (20 mM MOPS, pH 7.2, 25 mM b-glycerol phosphate,
5 mM EGTA, 1 mM sodium orthovanadate and 1 mM DTT),
20 µg of histone H1 (Biozol), 10 µl inhibitor cocktail (Biozol),
10 µl of [32P]-ATP-Mixture (75 mM magnesium chloride, 500 µM
ATP in assay dilution buffer) and 100 µCi [32P]-ATP
(3000 Ci/mmol, Hartmann Analytics, Braunschweig, Germany).
The kinase reaction was performed for 15 min under shaking at
30˚C. Following a brief centrifugation, the supernatant (25 µl)
was applied to phosphocellulose sheets, which have been rinsed
5 times with 1% phosphoric acid. Radioactivity was determined
using a liquid scintillation counter. 
Cellular uptake 
LXFL529L cells seeded into 10 cm Petri dishes were cultivated
for 24 h. Thereafter, they were incubated for 2 h with the respect-
ive compound in serum-containing medium. For each concentra-
tion two Petri dishes were treated in parallel. At the end of the
allotted time, substance-containing medium was removed and the
Petri dishes were washed twice with PBS. Cells were harvested by
scraping in Tris-buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl2,
0.1 mM EDTA) and cracked by 3 cycles of freezing and thawing in
liquid nitrogen. Centrifugation of the homogenate for 15 min at 
10 000 g yielded the cytosolic fraction in the supernatant to be
analysed separately. The remaining pellet was treated with Tris-
buffer containing 0.5% Triton® X-100 for solubilization of the
membrane proteins. The protein content of the samples was deter-
mined according to the method of Bradford. Subsequently, precip-
itation of the proteins and elution of the test compounds was
performed by addition of methanol (–20˚C). After centrifugation
for 15 min at 10 000 g the supernatant was applied to HPLC. 
HPLC determination of indirubin and indirubin-3¢-monoxime
was performed on a reversed phase column (RP 18 endcapped,
LiChroCART 125–4, Merck, Darmstadt, Germany) with UV
detection at 292 nm, using methanol/H2O (70/30) at 1 ml min–1.
Indirubin-5-sulfonate was determined using an aqueous solution
of tetrabutylammoniumbromide (5 mM) and methanol (40/60) as
mobile phase. Quantification was done by comparison with
external standards. Each sample was analysed at least twice. For
each concentration two Petri dishes were treated and analysed in
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are given as mean ± SD. 
Flow cytometry 
Cells were seeded into 10 cm Petri dishes and treatment started at
a cell density of 60–70% (logarithmical growth). After synchro-
nization and drug treatment, cells were trypsinized and centrifuged
at 200 g. The cell pellet was washed with PBS and fixed in 70%
ethanol (4˚C). Flow cytometry was performed as described previ-
ously (Marko et al, 1998). 
RESULTS 
Growth inhibition 
Indirubin, indirubin-3¢-monoxime and indirubin-5-sulfonate
(Figure 1) were tested for growth inhibitory activity using the
human large cell lung carcinoma line LXFL529L and the human
mammary carcinoma cell line MCF-7 (Table 1). In LXFL529L
cells indirubin-3¢-monoxime was clearly more active than
indirubin, however, no significant difference in growth inhibition
was detected between the two compounds on MCF-7 cells.
Indirubin-5-sulfonate, exhibiting the highest potency for in-vitro
inhibition of CDK1/cyclin B kinase from starfish oocytes (Hoessel
et al, 1999), was inactive up to 100 µM in both cell lines. 
Cellular uptake and subcellular localization of
indirubins 
To investigate potential causes for the discrepancy between the inhi-
bition of isolated CDKs and growth inhibitory properties in cell
culture, cellular uptake and subcellular distribution of the compounds
was determined. LXFL529L cells were incubated with the respective
compounds for 2 h and the cellular content was determined by HPLC
using UV detection. Incubation with 10 µM indirubin resulted in a
cellular content of 0.15 ± 0.08 µg mg–1 protein, 93 ± 6% being local-
ized in the particulate fraction. Incubation with 20 µM only margin-
ally enhanced the cellular content to 0.20 ±0.08 µg mg–1 protein, with
93 ± 6% in the particulate. Indirubin and indirubin-3¢-monoxime
were taken up to a comparable extent. Incubation with 10 µM
indirubin-3¢-monoxime resulted in a cellular content of 0.16 ± 0.01
µg mg–1 protein, but in contrast to indirubin a substantial proportion
of indirubin-3¢-monoxime was detected in the cytosol (43 ± 14%).
Incubation with 20 µM indirubin-3¢-monoxime only slightly
enhanced the cellular content (0.23 ± 0.03 µg mg–1 protein) with 44 ±
16% of the compound localized in the cytosol. Indirubin-5-sulfonate
was not detectable at all in the cells even after incubation with
concentrations as high as 50 µM. 
Based on these results, indirubin-3¢-monoxime, representing a
potent inhibitor of isolated CDK1/cyclin B with an IC50 of 0.18 µM
(Hoessel et al, 1999) that showed the highest growth inhibitory
efficacy was selected for the following mechanistic studies. 
Effects on cell cycle distribution and induction of
apoptosis 
Inhibition of cyclin-dependent kinases is expected to result in
changes of the cell cycle distribution. Therefore, the effect of
indirubin-3¢-monoxime on the cell cycle distribution of MCF-7
cells was determined by flow cytometry. MCF-7 cells were
synchronized by two different methods, to compare the effect of
indirubin-3¢-monoxime on cell populations with differential cell
cycle distribution after release from synchronization (Figure 2,
Table 2). Table 2 shows the differential effects of the two synchro-
nization protocols used in this study and shows the different
velocity by which the cells return to the unsynchronized cell cycle
distribution. Serum deprivation of MCF-7 cells for 48 h induced a
significant increase of cells in the G1/G0 phase of the cell cycle, as
well as a slight increase of cells in G2/M, concomitantly with a loss
of cells in S-phase (Table 2). 6 h after release by serum repletion,
control cells remained arrested in G1/G0, whereas already a reduc-
tion of cells in G2/M became apparent (Table 2). Cells treated with
indirubin-3¢-monoxime (20 µM) showed 6 h after release from
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Figure 1 (A) Indirubin, (B) indirubin-5-sulfonate (sodium salt), (C) indirubin-
3¢-monoxime 
Table 1 Growth inhibition of indirubin and derivatives in the sulforhodamine
B assay 
Compound
Growth inhibition, IC50 (µM)a
LXFL529L MCF-7 
Indirubin 9.9 ± 0.1 4.0 ± 2.0 
Indirubin-3¢-monoxime 3.0 ± 0.5 3.3 ± 0.4 
Indirubin-5-sulfonate ³ 100 ³ 100 
aGrowth inhibition was determined using the sulforhodamine B assay
(Skehan et al, 1990), incubation time 3 d. IC50 values were calculated as
survival of treated cells over control cells ´ 100 (T/C%); values are given as
mean ± SD of three separate assays, each done in quadruplicate. serum-deprivation a slight increase in G1/G0 (Figure 3A). 24 h
after release control cells exhibited a 10% reduction in G1/G0 and
an already normalized G2/M population (Table 2). In contrast, cells
treated with 2 µM indirubin-3¢-monoxime at the same time point
after serum replenishment showed a significant increase in G1/G0.
At concentrations ³5 µM this effect was enhanced and addition-
ally an increase of cells in G2/M was observed (Figure 3B; Figure
4A–C). Furthermore, at 10 µM indirubin-3¢-monoxime a small
sub-G1-peak became apparent, indicating the onset of apoptotic
cell death (Figure 4C). ELISA-based analysis of fragmented DNA
supported these results, revealing an initial increase even at 5 µM
indirubin-3¢-monoxime, which was strongly enhanced at 15 µM
(data not shown). 
Treatment of MCF-7 cells with nocodazole induced a strong
transient arrest in the G2/M phase of the cell cycle, concomitant
with a marked depletion of the G1/G0 population (Table 2). In the
untreated control, 6 h after withdrawal of nocodazole, the number
of cells in G2/M had already dropped by approximately 50% and
the cell number in G1/G0 had normalized (Table 2). In contrast,
treatment with indirubin-3¢-monoxime at concentrations ³5 µM
kept the cells in the G2/M phase and prevented an increase of the
G1/G0 cells (Figure 4D–F, Figure 5A). In the untreated control, 24 h
after withdrawal of nocodazole the number of cells in G2/M had
dropped further, heading to normal cell cycle distribution (Table 2).
In contrast, the presence of indirubin-3¢-monoxime (³5 µM)
induced a strong arrest in the G2/M phase of the cell cycle at the
same time point (Figure 4G–I, Figure 5B). In addition, at 10 µM
indirubin-3¢-monoxime a sub-G2-peak became apparent (Figure
4I), indicating the onset of apoptotic cell death. 
Inhibition of CDK activity in MCF-7 cells 
To investigate whether indirubin-3¢-monoxime affects CDK
activity in human tumour cells, we selected CDK1/cyclin B kinase
as a representative target. MCF-7 cells were synchronized by noco-
dazole treatment and subsequently incubated with indirubin-3¢-
monoxime or the solvent DMSO (1%) for 24 h (Figure 2) in
serum-containing medium comparable to the cell cycle experi-
ments (Figures 4G–I and 5B). After immunoprecipitation with a
monoclonal antibody raised against human CDK1, the phosphory-
lation of histone H1 was determined as a measure for CDK1
activity. Incubation with 5 µM indirubin-3¢-monoxime induced a
highly significant reduction of CDK1 activity (P < 0.005 compared
to the control), an effect which was enhanced by incubation with 10
µM (Figure 6). In comparison, incubation with olomoucine was
found to be less effective, inhibiting 50% of the kinase activity at
100 µM. In cells arrested by serum-deprivation, dose-dependent
inhibition of the intracellular CDK1 activity by indirubin-3¢-
monoxime was observed to a similar extent (data not shown). 
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Figure 2 Experimental design. aFor the cell cycle experiments depicted in
Figures 3A, B and 4 A–C serum depletion for 48 h was used as an
alternative synchronization method. Cells were kept for 48 h in serum-free
medium. bThereafter, to release the cells from the block serum was repleted.
At this time point, incubation with indirubin-3’-monoxime was started 
Table 2 Effects of synchronization and release on the cell cycle distribution of otherwise untreated MCF-7 cellsa
Serum deprivationb Nocodazolec
G1/G0 SG 2/M G1/G0 SG 2/M 
Untreated cellsd 50.7 ± 3.3 40.3 ± 2.3 9.1 ± 0.6 56.8 ± 2.0 37.5 ± 2.0 5.8 ± 1.1 
After synchronizatione 77.2 ± 3.6 8.1 ± 0.8 14.8 ± 2.9 13.0 ± 6.5 1.1 ± 1.5 86.0 ± 8.0 
6 h after releasef 78.4 ± 2.6 9.8 ± 3.5 11.8 ± 1.2 56.2 ± 1.2  6.7 ± 3.7 37.1 ± 5.5 
24 h after release 68.4 ± 3.2 24.1 ± 3.4 7.5 ± 2.2 52.2 ± 3.0 19.5 ± 1.3 28.2 ± 4.3 
aCell cycle distribution was determined by flow cytometry after DAPI staining. The data show representative experiments done
in duplicate. The whole experiment was repeated twice. Values are given as mean ± SD. bAfter plating, cells were cultivated for
24 h in the presence of 10% FCS. Thereafter, the cells were held for 48 h in serum-free medium. cAfter plating, cells were
allowed to settle for 24 h in serum containing medium. Thereafter, the cells were treated for 16 h with nocodazole (0.5 µg ml–1).
dCell cycle distribution 24 h after plating, immediately before synchronization. eAfter serum deprivation for 48 h or treatment for
16 h with nocodazole, respectively. f6 h after the end of the synchronization treatment by readdition of serum or removal of the
nocodazole containing medium. 
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Figure 3 Time- and concentration-dependent effect of indirubin-3¢-
monoxime on the cell cycle distribution of MCF-7 cells, synchronized by
serum deprivation. Cells were treated for 6 h (A) and 24 h (B) with indirubin-
3¢-monoxime. After DAPI staining, cell cycle distribution was determined by
flow cytometry. (n) G1/G0, (O) G2/M, (s) S, (à) debris. For each concentration
2 Petri dishes were treated in parallel, the whole experiment was repeated
twice. The values are given as mean ± SD Reduction of the active CDK1/cyclin B complex 
Furthermore, we addressed the question whether treatment with
indirubin-3¢-monoxime influences the protein levels of cyclin B
and CDK1 as well as the amount of cyclin B in complex with the
kinase. MCF-7 cells were arrested by nocodazole treatment. After
release, cells were incubated with 5 µM indirubin-3¢-monoxime in
serum-containing medium. For each time-point, a vehicle control
was prepared in parallel. The total cellular content of cyclin B and
CDK1 was determined by Western blot analysis using monoclonal
antibodies. The chemoluminescent signal of the protein bands was
quantified and calculated as percent of the respective vehicle
treated control. After 1 h treatment, no significant changes in the
total cyclin B and CDK1 protein levels were observed. The results
after 3 h incubation indicate an increase of the protein levels of
cyclin B and CDK1, but were not significant. By immunopreci-
pitation using a monoclonal anti-CDK1 antibody, followed by
Western blotting with an antibody raised against cyclin B, we deter-
mined the amount of cyclin B in the active complex with CDK1.
We observed a time-dependent change of cyclin B in complex
with CDK1 induced by incubation with indirubin-3¢-monoxime
(Figure 7). Comparable to the results concerning the total amount
of CDK1 and cyclin B, 1 h incubation resulted in a slight, not
significant reduction of cyclin B. After 3 h of treatment, a signi-
ficant increase of cyclin B in the active complex was detected 
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Figure 4 Effect of indirubin-3¢-monoxime on the cell cycle distribution
of MCF-7 cells. (A–C) Cells were synchronized by serum deprivation
(A) Control cells 24 h after readdition of serum. (B) 24 h incubation with 5 µM
indirubin-3¢-monoxime. (C) 24 h, 10 µM indirubin-3¢-monoxime. (D–I) Cells
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6 h. (F) 10 µM indirubin-3¢-monoxime, 6 h. (G) Control cells 24 h after
nocodazole treatment. (H) Incubation with 5 µM indirubin-3¢-monoxime for 
24 h. (I) 10 µM indirubin-3¢-monoxime, 24 h. Cells were stained with DAPI
and measured by flow cytometry. The charts show a representative
experiment (n = 3) 
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Figure 5 Time-and concentration-dependent effect of indirubin-3’-
monoxime on the cell cycle distribution of MCF-7 cells, synchronized by
nocodazole treatment. Cells were treated for 6 h (A) and 24 h (B) with
indirubin-3¢-monoxime. After DAPI staining, cell cycle distribution was
determined by flow cytometry. (n) G1/G0, (m) G2/M, (s) S, (à) debris. For each
concentration, 2 Petri dishes were treated in parallel, the whole experiment
was repeated twice. The values are given as mean ± SD 
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Figure 6 Inhibition of CDK1 kinase activity in MCF-7 cells. Cells were
synchronized by nocodazole treatment and subsequently incubated with the
respective compound for 24 h. Thereafter, immunoprecipitation was
performed using an antibody against human CDK1. Phosphorylation of
histone H1 was determined using 32P-ATP. The CDK1 activity is expressed
as % of the untreated control. The values are given a mean ± SD (n = 3) (P < 0.05). After 6 h incubation the total amount of cyclin B was
significantly increased, whereas the amount of cyclin B in
complex with CDK1 was significantly reduced (P < 0.05). A
significant reduction of the total CDK1 protein was observed after
24 h treatment, paralleled by the reduction of cyclin B in complex
with CDK1, whereas the total amount of cyclin B remained
elevated. 
DISCUSSION 
We have recently discovered, that indirubin-3¢-monoxime potently
inhibits cyclin-dependent kinases, such as CDK1/cyclin B,
CDK2/cyclin A and CDK2/cyclin E (Hoessel et al, 1999). Since
these observations were made using in-vitro kinase assays with
isolated enzyme preparations, the question needed to be addressed
whether CDK inhibition would also be seen in mammalian cells
and whether this could be relevant for the growth inhibitory prop-
erties of indirubins. We here exemplify for CDK1 that indirubin-
3¢-monoxime inhibits CDK activity in MCF-7 cells at
growth-inhibitory concentrations (Figure 6). Comparing the
results of the cell cycle experiments (Figure 5) with the effects on
CDK1 activity (Figure 6) demonstrates that despite the persisting
G2/M arrest of indirubin-3¢-monoxime treated cells, expected to
display high CDK1 activity in that cell cycle phase, in fact a dose-
dependent inhibition of CDK1 activity is observed, compared to
controls that have approached G1. It appears unlikely therefore that
the observed CDK1 activity inhibition is merely a reflection of
changed cell cycle distribution. 
Taking into account that the activity of isolated enzyme prepara-
tions of CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and
CDK5/p35 are inhibited in the same concentration range (Hoessel
et al, 1999), it can be expected, that in the cell in addition to CDK1
other CDKs are inhibited as well. This is supported by our findings
that indirubin-3¢-monoxime not only interferes with the release
from G2/M, as shown in cells arrested by nocodazole treatment,
but also prevents G1/S transition of cells synchronized in G1/G0 by
serum depletion. 
Concentrations of indirubin-3¢-monoxime that induce CDK1
inhibition in cell culture are significantly higher, however, than
those leading to the effective inhibition of isolated enzyme prepara-
tions. This reflects the potential influence of cellular uptake,
subcellular distribution, elimination or metabolism. Indirubin and
indirubin-3¢-monoxime are taken up into cells to a similar
extent. Despite significantly higher inhibitory potency of indirubin-
3¢-monoxime towards isolated CDK1/cyclin B kinase, indirubin-3¢-
monoxime exhibited only slightly enhanced growth inhibitory
288 D Marko et al
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Figure 7 (A) Total cellular content of cyclin B and CDK1 and of cyclin B in complex with CDK1 in MCF-7 cells, synchronized by treatment with nocodazole.
The cells were incubated with 5 µM indirubin-3¢-monoxime for 1 h, 3 h, 6 h and 24 h. Cell lysates were subjected to SDS PAGE (12% polyacrylamide) and
transferred onto nitrocellulose. Western blotting was performed using monoclonal antibodies against human CDK1 or cyclin B, respectively. For detection of
cyclin B in complex with CDK1, immunoprecipitation with a monoclonal antibody against CDK1 was followed by a Western blot using a monoclonal antibody
against cyclin B. The protein levels are expressed as percent of the respective vehicle control at that time point. The values are the means ± SE of 3
independent experiments. (B) Immunoprecipitation (anti-CDK1), followed by Western blotting (anti-cyclin B) of MCF-7 cells 24 h after release from nocodazole
treatment, incubated with 5 µM indirubin-3¢-monoxime or vehicle control after synchronization. The figure shows a representative experiment, repeated twicepotency (Table 1). Apparently, differential subcellular distribution of
the two compounds is of great additional influence. Whereas
indirubin is predominantly localized in the particulate fraction,
containing cellular membranes and nuclei, up to 44% of indirubin-
3¢-monoxime is detected in the cytosol. The crystal structure data
of the indirubin-3¢-monoxime complex with CDK2 show that the
inhibitor binds to the ATP-binding site of the CDK subunit (Hoessel
et al, 1999). The protein kinase CDK1/cyclin B plays a crucial role
in the onset of mitosis in human cells. The CDK1/cyclin B1
complex accumulates in the cytoplasm during the G2 phase, being
translocated into the nucleus at the beginning of mitosis (Takizawa
et al, 1999). Thus, for inhibitors targeting the CDK subunit, as it has
been shown for indirubin-3¢-monoxime (Hoessel et al, 1999),
enhanced localization in the cytosol, might compromise the avail-
ability of the compound for inhibition in the relevant cellular
compartment, the site of kinase activity: the nucleus. 
The introduction of a sulfonate group into position 5 of indirubin
potentiated the inhibition of isolated CDK1/cyclin B (Hoessel et al,
1999). However, the growth inhibitory properties are completely
extinguished because this compound does not penetrate into the cell. 
Furthermore, we investigated whether the inhibition of intracel-
lular CDK1 activity is associated with changes in the expression of
CDK1 or the regulatory subunit cyclin B. In MCF-7 cells arrested
with nocodazole and treated with 5 µM indirubin-3¢-monoxime
after release, a significant increase of the cyclin B level was
detected after 6 and 24 h. The enhanced cyclin B levels (compared
to untreated control) appear to reflect the effective arrest of the
indirubin-3¢-monoxime treated cells in G2/M (Figure 5), whereas
control cells already move towards normal cell cycle distribution
(Table 2). In contrast, after 24 h incubation, a significant decrease
of the total CDK1 protein is observed, paralleled by the reduction
of cyclin B in complex with CDK1 (Figure 7). At that time point,
cells are still effectively arrested in G2/M (Figure 5B), where high
levels of the active CDK1/cyclin B complex are to be expected,
compared to control cells already found predominantly in G1
(Table 2). The cell cycle passage in mammalian cells is regulated
by a complex system of activating and inhibiting factors. The
different cyclin-dependent kinases act in distinct phases of the cell
cycle. Thus, potent and selective inhibitors of CDKs might induce
different effects on the cell cycle distribution, depending on the
respective phase in which the cells are targeted. CDK1 and CDK2
play key roles at two different control points of the cell cycle.
CDK2 is involved in the regulation of the G1/S transition, whereas
CDK1 is essential for the entry into mitosis. Our results suggest
that indirubin-3¢-monoxime interferes with cell cycle regulation at
both restriction points. Olomoucine, an inhibitor of CDK1 and
CDK2 kinases, has been reported to arrest cells both at the G1/S
and the G2/M boundaries (Abraham et al, 1995). 
We have previously shown, that treatment with low concentra-
tions of indirubin-3¢-monoxime arrests non-synchronized cells in
the G1 phase of the cell cycle and that at concentrations ³5 µM an
additional accumulation in G2/M is observed (Hoessel et al, 1999).
These data are consistent with our present results on the cell cycle
effects in MCF-7 cells, synchronized by serum deprivation (Figure
3). In non-synchronized cells, the greatest proportion of the cells is
in the G1 phase. Synchronization by serum deprivation induces an
arrest mainly in G1, with some additional increase at G2/M (Table
2). Thus, serum deprivation should pronounce effects of drugs
acting at the G1/S transition. In line with this argument, an increase
of the cell population in G1 at low substance concentration (2 µM)
is observed after 24 h treatment with indirubin-3¢-monoxime
(Figure 3). Together with the data on non-synchronized cells
(Hoessel et al, 1999), these results indicate that indirubin-3¢-
monoxime is active on CDK2 kinases interfering with the G1/S
transition in cell culture. However, at higher drug concentrations
(³5 µM) an additional accumulation in G2/M has been observed
(Hoessel et al, 1999). This is consistent with the present results
showing indirubin-3¢-monoxime induced inhibition of MCF-7
cells, arrested in G2/M by nocodazole treatment, to further
progress into G1 (Figure 4 D–I, Figure 5). Moreover, after 24 h at
10 µM indirubin-3¢-monoxime, a sub-G2 peak became apparent,
indicating the onset of apoptotic cell death (Figure 4 I). 
Taken together, our results clearly show that indirubin-3¢-
monoxime exerts potent tumour cell growth inhibition and that this
relates to inhibition of CDKs. As a result, progress through the cell
cycle is blocked at G1/S and G2/M, events that might result in the
induction of apoptosis. 
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